Lusiadas S.A.

Lisbon 18 trials 8 recruiting

18 Registered trials

8 Currently recruiting

Organisation

Lusiadas S.A.

Location

Lisbon, Portugal

Identifier

ORG-100044926

Address

Rua Abilio Mendes 12, 1500-458, Portugal

Departments

Cardiology
Cardiology Department
Dermatology
Gastroenterology
Oncology
Oncology Center
Oncology Department
Rheumatology
Serviço de Gastrenterologia
Serviço de Gastroenterologia
Unidade de Oncologia

Clinical trials at this site (18)

Search interface

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending

2025-523869-22-00 advanced or metastatic extrapulmonary neuroendocrine ca 5
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 10 2024-10-02
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) i… Recruiting

2024-516633-12-00 Locally advanced/ metastatic gastroesophageal junction 5 2025-06-30
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
Clinical study to demonstrate the same clinical efficacy and tolerability of budesonide orodispersible tablets (taken twice a day compared t… Recruiting

2024-515229-26-00 eosinophilic esophagitis 5 2021-05-21
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended

2023-507342-84-00 Bladder Cancer 5 2021-10-26
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24